Wire · opportunities
LDL-cholesterol lowering medication linked to lower mortality in high-risk patients
◆ Sectors
Biotech
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
A clinical trial found that the cholesterol-lowering drug evolocumab significantly reduced all-cause mortality in high-risk patients without prior heart attack or stroke, including those with high-risk diabetes, compared to placebo.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have clear evidence that adding evolocumab to standard therapy cuts mortality in high-risk patients without previous heart events. This opens opportunities to target broader patient groups and push earlier intervention in lipid management.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics
Biotechcholesterolcardiovascularclinical-trialmortalityevolocumab